Funding
Accelerator investment · Healthtech

BGV backs Deconvolvr's software for cancer biopsy analysis

Deconvolvr develops bioinformatics software to interpret molecular signals in cancer biopsy samples and support more personalised treatment decisions.

By RoundOS Funding desk

Deconvolvr became part of Bethnal Green Ventures' investment portfolio through its Spring 2026 Tech for Good programme. BGV announced the cohort on April 21.

Separating signals in cancer biopsies

Deconvolvr is developing bioinformatics software that separates signals from cancer cells and surrounding tissue in biopsy data. The Edinburgh company aims to improve prognostic testing and support personalised decisions for men with prostate cancer.

Funding history

Accelerator investment · This roundUndisclosed

Sources

  1. Announcing our Spring 2026 cohortbethnalgreenventures.com · Apr 21, 2026
  2. uk.linkedin.com
  3. find-and-update.company-information.service.gov.uk

Similar rounds

All Healthtech rounds →
Nanochap

Develops retinal and cortical brain-computer interfaces that use electrical stimulation to create artificial visual perception.

CN¥500MSeries C+ · Nov 3, 2026
1nhaler

1nhaler develops a compact, single-dose dry powder inhaler made predominantly from cardboard.

£2.2MFollow-on funding · Nov 3, 2026
Esonitro

Esonitro develops flexible neural electrodes and brain-computer interface technology, including its movable NeuroWorm electrode.

~CN¥100MAngel+ · Nov 2, 2026
OBSESS

OBSESS connects people with sports venues, gyms, trainers, nutrition providers and fitness brands through a shared digital marketplace.

~₹30MAngel · Nov 2, 2026

Related